CORD BLOOD REGULATORY T CELL THERAPEUTICS
Cellenkos is a Clinical-Stage Biotechnology Company that is developing Allogeneic, Tissue-Targeted, Immune T-Regulatory Cell Therapies to Treat Autoimmune Diseases & Inflammatory Disorders.
Our Pipeline
![](/cellenkos-pipeline-Q1-2024.png)
![](/ic-protects-v1.png)
T-REGs protect the body from attack of T cells
Regulatory T cells (T-REGS) suppress inflammation and combat T cells and other compartments of the immune system from attacking our body.
Defective T-REGS lead to autoimmune diseases
Defective T-REGs can no longer protect the body from the harmful effect of T cells which lead to certain autoimmune diseases including lupus, multiple sclerosis, rheumatoid arthritis and inflammatory disorders like Crohn’s disease and bone marrow failure syndromes like aplastic anemia.
![](/ic-defective-v1.png)
![](/ic-defends-v1.png)
CK0801 is first in class, cord blood derived regulatory T cell product
Clinically manufactured using the Cellenkos’ proprietary platform, CK0801 shows superior T cell suppression and anti-inflammatory properties.
CK0801 overcomes existing T-REG defect
CK0801 infusion replaces the defective T-REGs and protects the body from T cell attack.
![](/ic-replaces-v1.png)
![](/ic-restores-v1.png)
CK0801infusion leads to disease control
By preventing T cell attack against one’s own body, CK0801 restores immune homeostasis. This leads to disease control.